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Abstract
Background: Significant fatigue is a frequent reason for seeking medical advice in the general population. Patients,
however, commonly feel their complaint is ignored. This situation may be because clinicians perceive fatigue to be
benign, unrelated to traditional biomedical outcomes such as premature mortality. The present study aimed to
investigate whether an association between significant fatigue and mortality actually exists, and, if so, to identify
potential mechanisms of this association.
Methods: A population-based cohort of 18,101 men and women aged 40–79 years who completed a measure of
fatigue (Short Form 36 vitality domain, SF36-VT) in addition to providing information on possible confounding
factors (age, sex, body mass index, marital status, smoking, education level, alcohol consumption, social class,
depression, bodily pain, diabetes, use of β blockers, physical activity and diet) and mechanisms (haemoglobin,
C-reactive protein and thyroid function) were followed up prospectively for up to 20 years. Mortality from all causes,
cancer and cardiovascular disease was ascertained using death certification linkage with the UK Office of National
Statistics.
Results: During 300,322 person years of follow-up (mean 16.6 years), 4397 deaths occurred. After adjusting for
confounders, the hazard ratio (HR) for all-cause mortality was 1.40 (95 % confidence interval [CI] 1.25–1.56) for those
reporting the highest fatigue (bottom SF36-VT quartile) compared with those reporting the lowest fatigue (top
SF36-VT quartile). This significant association was specifically observed for those deaths related to cardiovascular
disease (HR 1.45, 95 % CI 1.18–1.78) but not cancer (HR 1.09, 95 % CI 0.90–1.32). Of the considered mechanisms,
thyroid function was most notable for attenuating this association. The risk of all-cause mortality, however,
remained significant even after considering all putative confounders and mechanisms (HR 1.26, 95 % CI 1.10–1.45).
Conclusions: High levels of fatigue are associated with excess mortality in the general population. This commonly
dismissed symptom demands greater evaluation and should not automatically be considered benign.
Keywords: Fatigue, Mortality, Cardiovascular, Cancer
* Correspondence: neilbasu@abdn.ac.uk
1Epidemiology Group, Institute of Applied Health Sciences, School of
Medicine & Dentistry, University of Aberdeen, Foresterhill, Aberdeen,
Scotland AB25 2ZD, UK
Full list of author information is available at the end of the article
© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Basu et al. BMC Medicine  (2016) 14:122 
DOI 10.1186/s12916-016-0662-y
Background
Fatigue is a normal experience, but for some persons its
impact is profound, resulting in concerns regarding their
health. In fact, fatigue is one of the commonest com-
plaints reported in primary care, constituting up to 20 %
of all presentations [1, 2] and the principal reason for
consultation in 5-7 % of cases [1–3].
The psychosocial consequences of fatigue are becom-
ing increasingly recognised. It is strongly associated with
poor long-term quality of life [4] and work ability [5]. In-
deed, excessively fatigued workers are estimated to cost
employers $136.4 billion/year in the USA alone [6]. Des-
pite this, patients’ commonly consider the symptom to
be ignored by medical practitioners [7] and approxi-
mately 75 % of these patients are not followed up [8]. It
may be that doctors are justifiably selective in their
follow-up of these patients; however, this paucity of at-
tention may also reflect the perception that fatigue does
not affect traditional biomedical outcomes such as pre-
mature mortality.
A few studies have reported a possible association be-
tween fatigue and mortality, although these suffer from
significant methodological limitations: (1) small sample
sizes which prohibit the inspection of cause-specific
mortality, (2) non-generalisable samples, (3) the use of
non-validated single item measures of fatigue which pre-
clude evaluation of dose response and (4) a limited con-
sideration of potential confounders and mechanisms,
clearly crucial in the context of such a multifactorial
symptom [9, 10].
So why could fatigue result in premature mortality?
Some have plausibly hypothesised that fatigue leads to
harmful changes in behaviour [9]. Alternatively, the
underlying pathophysiology of the symptom itself could
lead to poor outcomes – fatigue is a commonly recognised
feature of dysfunctional physiology, for example it is a
cardinal feature of low rates of metabolism due to
hypothyroidism, which in turn is an established risk factor
of cardiovascular disease (CVD)-related mortality [11].
The aim of this study was to describe and then under-
stand the reasons for an association between fatigue and
mortality (both all-cause and cause-specific) in a large
prospective population-based cohort.
Methods
Study design and sample
Participants were drawn from the European Prospective
Investigation into Cancer and Nutrition (EPIC)-Norfolk
study. The study methodology and sample distribution
have been previously reported in detail [12]. In brief, this
prospective cohort study recruited members of the general
population, aged 40–79 years at the baseline, using general
practice age-sex registers from the region of Norfolk – a
relatively stable and immobile population in the UK.
Participants attended for baseline health assessments be-
tween 1993 and 1997 and have since been followed up by
way of additional health assessments, questionnaires and
national registry data linkage. Ethical approval was ob-
tained from the Norwich Research Ethics Committee.
Prognostic factor of interest
Investigating the determinants of mortality is one of the
aims of this cohort. In this specific study, the prognostic
factor of interest was fatigue, defined according to the
UK version of the Short Form 36 vitality domain (SF36-
VT). Although there is no single accepted measure of fa-
tigue, the SF36-VT is commonly used and validated in
studies of both diseased and general populations [13, 14].
In fact, it is employed as a gold standard tool to support
the development of other fatigue assessment instruments
[15]. Collected within the 18-month follow-up study ques-
tionnaire, the SF36-VT consists of four questions which
refer to the previous 4 weeks: (1) Did you feel full of life?
(2) Did you have a lot of energy? (3) Did you feel worn
out? (4) Did you feel tired? These were summed and
transformed into a 0–100 scale (where a high score repre-
sented low fatigue levels) using established scoring algo-
rithms [14]. For the purposes of analysis, the final scores
were categorised according to quartiles derived from the
whole sample.
Outcome ascertainment
Mortality was ascertained using death certification link-
age with the UK Office of National Statistics (ONS) at
follow-up (censored in 2013). In addition to data on all-
cause mortality, deaths specifically attributed to CVD
(defined by International Classification of Disease [ICD],
9:401–448 or ICD 10:I10-I79) or cancer (defined by ICD
9:140–208 or ICD 10:C00-C97) were recorded.
Putative confounders/mechanisms
Multiple putative covariates, commonly considered by
clinicians when evaluating the complaint of fatigue, were
measured at baseline.
The mechanisms of fatigue are poorly described and
some may also be considered confounders. We under-
took a conservative approach by assuming that a factor
fulfilling the statistical criteria for a confounding variable
(i.e. a variable that is significantly associated with both fa-
tigue and mortality) was a confounder. A covariate not
fulfilling such criteria was considered to be a possible
mechanism.
The covariates were collected by trained staff accord-
ing to standardised protocols:
Self-reported measures
A survey capturing demographic and lifestyle information
was conducted at baseline. This included age, gender and
Basu et al. BMC Medicine  (2016) 14:122 Page 2 of 8
marital status. As with previous EPIC analyses, social class
was categorised according to the Registrar General’s occu-
pation classification scheme and further collapsed into
manual or non-manual categories [16]. Education status
of participants was defined according to whether or not
they reached A-level standard (the senior secondary edu-
cation examination in England). Self-reported total alcohol
consumption was quantified as the total units of alcohol
(1 unit equates about 8 g) consumed in a week and smok-
ing as current/non-current. In order to ascertain the
prevalence of baseline morbidity, participants were asked
‘Has your doctor ever told you have the following?’
followed by a list of illnesses which included cancer, dia-
betes, depression, heart attack and stroke. The SF36 bodily
pain domain (simultaneously collected with the SF36-VT)
was scored and transformed to a 0–100 scale employing
validated methods [14]. As with SF36-VT, a high score
represented a good health state, that is, low pain. Physical
activity was assessed using the EPIC-validated question-
naire [17] which rated participants as inactive, moderately
inactive, moderately active or active. The consumption of
fruit and vegetables (g/day) was determined by the EPIC
Food Frequency Questionnaire, also a previously well-
described and validated tool [18] which asks participants
to quantify their average consumption of a number of food
items over the past year. Medication use, including aspirin,
was self-reported and captured in the baseline survey.
Clinical measures
Height and weight were assessed and the body mass
index subsequently calculated (weight[kg]/(height[m2]).
This has been categorised according to World Health
Organisation definitions [19].
Non-fasting blood samples were collected. AutoDELFIA
time-resolved fluoroimmunoassay kits (Wallac, Finland)
were used to assay thyroid-stimulating hormone (TSH)
levels (hypothyroid status: >4.0 mU/l) in order to evaluate
thyroid status; serum concentrations of the inflammatory
marker C-reactive protein (CRP) were measured using a
high-sensitivity assay on an Olympus AU640 Clinical
Chemistry Analyser (Olympus UK Ltd, Watford, UK); and
a Coulter MD18 Haematology Analyzer (Addenbrookes
Hospital, Cambridge, UK) measured haemoglobin (Hb)
status to enable assessment for anaemia (moderate an-
aemia defined as Hb < 110 g/L [20]).
Statistical analysis
The cross-sectional relationship between quartiles of fa-
tigue severity and other putative confounders was first
described using Chi-squared tests (for categorical con-
founder data) and ANOVA (for continuous confounder
data), as appropriate.
Cox proportional hazards models were then employed to
examine the longitudinal relationships between quartiles of
fatigue and subsequent all-cause mortality over the follow-
up period. First, an unadjusted model was developed
(model A). Then, participants with a history of significant
CVD (stroke and/or myocardial infarction) or cancer at
baseline were excluded in order to avoid major confound-
ing (model B).
Using simple descriptive statistics, as appropriate, the
associations between the covariates of interest and fatigue
and mortality, respectively, were calculated. Those covari-
ates statistically associated (p < 0.05) with both SF36 vital-
ity and mortality were considered to be confounders and
those not were considered as possible mechanisms. Mech-
anistic factors are on the causal pathway between an ex-
posure and an outcome; if adjusted for in the analysis,
they will attenuate the observed exposure–outcome asso-
ciation. We tested our proposed ‘putative mechanisms’ by
adjusting for them in the analysis with the expectation
that if they are indeed mechanisms then the magnitude of
association between fatigue and mortality will be reduced.
Confounders were grouped and introduced (model C)
and then the influence of each possible mechanism was
evaluated by submitting these, in isolation, to this model.
Subsequently, all putative confounders and mechanisms
were advanced together in a single model.
To better determine the precise causes of any ob-
served mortality, the modelling process was repeated to
examine the longitudinal relationship between quartiles
of fatigue and subsequent (1) CVD-related mortality and
(2) cancer-related mortality.
Last, models were re-run with the exclusion of all
participants who died within 2 years of completing
SF36-VT in order to investigate the potential for reverse
causality, that is, the possibility of a significant subclin-
ical disease causing fatigue.
Analyses were undertaken using SPSS version 22.0
(IBM, Chicago, IL, US). The proportional hazard as-
sumption was checked by introducing an interaction
term of time and vitality and was found not to be vio-
lated. All reported p-values are for two-sided significance
tests and effect sizes are expressed as hazard ratios (HR)
with 95 % confidence intervals (CI).
Results
Of the 25,639 participants who attended the baseline
health assessment, complete SF36-VT data were available
for 18,101. In this sample, there were a total of 4397
deaths (CVD: 1410, cancer: 1573, other causes: 1414) with
over 300,322 person years of follow-up (mean 16.6 years).
Sample characteristics by SF36-VT quartile, where
quartile 1 (SF36-VT: 76–100) represents low levels of fa-
tigue and quartile 4 (SF36 VT: 0–49) represents high
levels of fatigue, are described in Table 1. Quartile 1 par-
ticipants were statistically more likely to be older, of fe-
male sex, married, obese, physically inactive, depressed,
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Table 1 Sample characteristics by SF36-VT quartiles of 18,101 EPIC-Norfolk participants
Characteristic N Total Q1 (76–100) Q2 (65–75) Q3 (50–64) Q4 (0–49) p-value
Agea (years) 18,101 59.0 ± 9.1 59.2 ± 8.7 59.0 ± 9.1 59.2 ± 9.3 58.6 ± 9.4 0.008
Sex 18,101 <0.001
Male 7943 (43.9) 2186 (49.7) 2322 (46.0) 1842 (40.9) 1593 (38.3)
Female 10,158 (56.1) 2209 (50.3) 2725 (54.0) 2659 (59.1) 2565 (61.7)
Body mass index (kg/m2) 18,064 <0.001
<18.5 83 (0.5) 13 (0.3) 19 (0.4) 23 (0.5) 28 (0.7)
18.5–25 7234 (40.1) 1891 (43.1) 2078 (41.2) 1721 (38.3) 1544 (37.3)
25–30 8123 (45.0) 2029 (46.3) 2289 (45.4) 2021 (44.9) 1784 (43.1)
>30 2624 (14.5) 451 (10.3) 654 (13.0) 732 (16.3) 787 (19.0)
Education 18,094 <0.001
Lower than A-level 8255 (45.6) 1912 (43.5) 2232 (44.3) 2065 (45.9) 2046 (49.2)
At least A-level 9839 (54.4) 2481 (56.5) 2812 (55.8) 2435 (54.1) 2111 (50.8)
Married 18,009 <0.001
Yes 14,681 (81.5) 3613 (82.6) 4184 (83.4) 3648 (81.5) 3236 (78.2)
Nob 3328 (18.5) 763 (17.4) 834 (16.6) 830 (18.5) 901 (21.8)
Social Class 17,757 <0.001
Manual 6725 (37.9) 1561 (36.2) 1778 (35.9) 1696 (38.4) 1690 (41.5)
Non-manual 11,032 (62.1) 2753 (63.8) 3178 (64.1) 2716 (61.6) 2385 (58.5)
Physical activity 18,101 <0.001
Inactive 5226 (18.7) 1019 (23.2) 1321 (26.2) 1372 (30.5) 1514 (36.4)
Moderately inactive 5287 (23.3) 1246 (28.4) 1519 (30.1) 1324 (29.4) 1198 (28.8)
Moderately active 4210 (29.2) 1092 (24.8) 1230 (24.4) 1022 (22.7) 886 (20.8)
Active 3378 (28.9) 1038 (23.6) 977 (19.4) 783 (17.4) 580 (13.9)
Depression 18,101 <0.001
Yes 2554 (14.1) 315 (7.2) 547 (10.8) 645 (14.3) 1047 (25.2)
No 15,547 (85.9) 4080 (92.8) 4500 (89.2) 3856 (85.7) 3111 (74.8)
Diabetes 18,101 <0.001
Yes 392 (2.2) 77 (1.8) 92 (1.8) 101 (2.2) 122 (2.9)
No 17,709 (97.8) 4318 (98.3) 4955 (98.2) 4400 (97.8) 4036 (97.1)
Bodily pain (SF36) 18,080 74.5 ± 23.0 87.7 ± 15.5 79.7 ± 18.8 70.7 ± 21.8 57.7 ± 24.6 <0.001
Fruit and vegetable consumption (g/day) 17,621 522.6 ± 257.0 539.8 ± 270.6 527.8 ± 245.2 517.8 ± 252.9 503.0 ± 259.3 <0.001
Alcohol consumption (g/day) 17,621 8.6 ± 12.7 9.3 ± 13.4 9.1 ± 12.8 8.2 ± 12.3 7.7 ± 12.4 <0.001
Beta blocker use 18101 <0.001
Yes 1138 (6.3) 215 (4.9) 278 (5.5) 323 (7.2) 322 (7.7)
No 16,963 (93.7) 4180 (95.1) 4769 (94.5) 4178 (92.8) 3836 (92.3)
Thyroid stimulating hormone (mU/L) 9761 0.265
High (≥4) 8857 (90.7) 2191 (90.35) 2445 (90.2) 2246 (91.7) 1975 (90.8)
Low (<4) 904 (9.3) 234 (90.7) 266 (9.8) 204 (8.3) 200 (9.2)
CRP (mg/L) 12,993 3.1 ± 6.2 3.1 ± 5.6 3.1 ± 6.4 2.9 ± 5.4 3.3 ± 7.3 0.223
Haemoglobin (g/dL) 12,971 0.886
High (≥11) 12,793 (98.6) 3138 (98.7) 3553 (98.5) 3220 (98.7) 2882 (98.6)
Low (<11) 178 (1.37) 41 (1.3) 54 (1.5) 43 (1.3) 40 (1.4)
p values indicate levels of significance across all quartiles
Data presented as mean (SD) for all continuous variables and number (%) for categorical variables
aat SF36 completion bincludes single, widowed, seperated and divorced
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report higher pain, and consume more fruit and vegeta-
bles when compared to those within quartile 4. In con-
trast, laboratory measures such as TSH, CRP and Hb
were not statistically different across fatigue quartiles
and so were not considered to be confounders. All
other covariates fulfilled the criteria for confounding
(Additional file 1: Table S1).
Table 2 shows the absolute risks and hazard ratios for
all-cause mortality by quartiles of SF36-VT. All models
consistently indicated that participants reporting the
highest fatigue (SF36-VT quartile 4) were at significantly
higher risk of mortality over the follow-up period than
those reporting the lowest fatigue (SF36-VT quartile 1).
The magnitude of this risk following exclusion of those
with a history of CVD (n = 1533) and cancer (n = 1410)
and then adjustment of other confounders (model C: HR
1.40, 95 % CI 1.25–1.56) was attenuated by thyroid func-
tion (model E: HR 1.26, 95 % CI 1.10–1.45) and less so
by CRP (model F: HR 1.39, 95 % CI 1.21–1.60).
On further inspection of disease-specific causes of
mortality, participants with high fatigue were at greater
risk of CVD-related death (Table 3) (model C: con-
founder adjusted HR 1.45, 95 % CI 1.18–1.78).
In contrast, no significantly increased risk of cancer-
related deaths was observed in any of the adjusted
models (Table 4). Because cancer and CVD accounted
for the majority of deaths, the apparent excess of mortal-
ity associated with fatigue appears to be mostly driven
by CVD-related deaths. As with all-cause mortality,
thyroid function (model E: HR 1.31, 95 % CI 1.03–1.68)
and CRP (model F: HR 1.38, 95 % CI 1.07–1.79) attenuated
the association between high fatigue and mortality over the
period of follow-up. Despite adjusting for all putative con-
founders and mechanisms, the risk remained pronounced
for both all-cause mortality (fully adjusted: HR 1.24, 95 %
CI 1.05–1.46) and a similar magnitude of risk for CVD-
related mortality (fully adjusted: HR 1.26, 95 % 0.93–1.70).
Finally, the effect of excluding all deaths occurring
within 2 years of follow-up (n = 4) upon the final models
was negligible.
Discussion
In this large population-based prospective study with
long-term follow-up, fatigue was significantly associated
with premature mortality, even after adjusting for multiple
potential confounders. Compared with those in the lowest
quartile of reported fatigue levels, participants in the high-
est quarter of reported fatigue levels had a 40 % higher
risk of premature mortality. This association was observed
for CVD-related, but not cancer-related, deaths. Thyroid
status and CRP level attenuated these associations al-
though these do not entirely explain the mechanisms
which underpin this concerning observation.
As with all studies of this nature, the results must be
considered in the context of some possible limitations.
First, although general practices in the UK are consid-
ered ideal population sample frames (because almost all
Table 2 The risks of all-cause mortality by SF36 vitality score in the EPIC-Norfolk study
Mortality N (%) SF36 vitality score quartile p-valuea
76–100 65–75 50–64 0–49
Model A: unadjusted full dataset
HR (95 % CI)
4397/18,101 (24.3 %) 928/4395 (21.1 %) 1103/5047 (21.9 %) 1154/4501 (25.6 %) 1212/4158 (29.1 %) <0.001
1 (reference) 1.04 (0.96–1.14) 1.27 (1.17–1.39) 1.49 (1.36–1.62)
Model B: unadjusted with removal
of baseline CVD/cancer
HR (95 % CI)
3637/16,409 (22.2 %) 825/4097 (20.1 %) 945/4657 (20.3 %) 944/4049 (23.3 %) 923/3606 (25.6 %) <0.001
1 (reference) 1.01 (0.92–1.11) 1.20 (1.10–1.32) 1.34 (1.22–1.47)
Model C: confounders
HR (95 % CI)
3388/15,577 (21.8 %) 771/3899 (19.8 %) 886/4442 (19.9 %) 880/3837 (22.9 %) 851/3399 (25.0 %) <0.001
1 (reference) 1.02 (0.93–1.13) 1.21 (1.10–1.34) 1.40 (1.25–1.56)
Model D: confounders + Hb
HR (95 % CI)
3388/15,577 (21.8 %) 771/3899 (19.8 %) 886/4442 (19.9 %) 880/3837 (22.9 %) 851/3399 (25.0 %) <0.001
1(reference) 1.01 (0.91–1.13) 1.24 (1.12–1.39) 1.40 (1.24–1.58)
Model E: confounders + TSH
HR (95 % CI)
3388/15,577 (21.8 %) 771/3899 (19.8 %) 886/4442 (19.9 %) 880/3837 (22.9 %) 851/3399 (25.0 %) <0.001
1 (reference) 0.97 (0.86–1.09) 1.23 (1.09–1.39) 1.26 (1.10–1.45)
Model F: confounders + CRP
HR (95 % CI)
3388/15,577 (21.8 %) 771/3899 (19.8 %) 886/4442 (19.9 %) 880/3837 (22.9 %) 851/3399 (25.0 %) <0.001
1 (reference) 1.06 (0.94–1.19) 1.24 (1.10–1.40) 1.39 (1.21–1.60)
Model G: confounders + Hb,
CRP, TSH
HR (95 % CI)
3388/15,577 (21.8 %) 771/3899 (19.8 %) 886/4442 (19.9 %) 880/3837 (22.9 %) 851/3399 (25.0 %) 0.001
1 (reference) 1.00 (0.87–1.15) 1.26 (1.09–1.46) 1.24 (1.05–1.46)
aAcross quartiles
Model A: unadjusted; Model B: unadjusted with removal of baseline CVD/cancer; Model C: Model B + statistically proven confounders – age, gender, body mass
index, marital status, smoking, education, alcohol, social class, diet, physical activity, beta blocker, depression, pain, diabetes; Model D: Model C plus Hb adjusted;
Model E: Model C plus TSH adjusted; Model F: Model C plus CRP adjusted; Model G: Model C plus Hb, CRP and TSH adjusted
CI confidence interval, CRP C-reactive protein, CVD cardiovascular disease, Hb haemoglobin, HR hazard ratio, TSH thyroid-stimulting hormone
Basu et al. BMC Medicine  (2016) 14:122 Page 5 of 8
people are registered to a general practitioner through
the National Health Service), only 40–45 % of registrants
provided baseline data, of which approximately 30 % did
not complete the SF36-VT questionnaire. Nonetheless,
previous descriptions of this cohort have failed to iden-
tify significant differences in population characteristics
when compared to other national samples, except for a
slightly lower prevalence of smokers [12], and no mater-
ial differences in background characteristics were identi-
fied between SF36-VT responders and non-responders.
Overall, these results appear generalisable when applied
to middle- to old-aged members of the general popula-
tion, although, owing to the study design, they are un-
likely to fully apply to typical healthcare attendees
principally presenting with significant fatigue. It is antici-
pated that such persons will complain of more severe
levels of fatigue compared to this study’s modest defin-
ition of high fatigue (a self-reported score within the top
25 % of the general population over a period of 1 month).
Chronic fatigue disorders, for example, are frequently
Table 3 The risks of cardiovascular disease related mortality by SF-36 vitality score in the EPIC-Norfolk study
Mortality SF-36 vitality score quartiles p-valuea
76–100 65–75 50–64 0–49
Model A: unadjusted full dataset
HR (95 % CI)
1 (reference) 0.98 (0.84–1.15) 1.25 (1.07–1.46) 1.63 (1.40–1.89) <0.001
Model B: unadjusted with removal
of baseline CVD/cancer
HR (95 % CI)
1 (reference) 0.92 (0.77–1.09) 1.18 (1.00–1.40) 1.41 (1.19–1.67) <0.001
Model C: confounders
HR (95 % CI)
1 (reference) 0.93 (0.78–1.12) 1.21 (1.00–1.45) 1.45 (1.18–1.78) <0.001
Model D: confounders + Hb
HR (95 % CI)
1(reference) 0.93 (0.77–1.13) 1.21 (1.00–1.48) 1.43 (1. 15–1.78) <0.001
Model E: confounders + TSH
HR (95 % CI)
1 (reference) 0.85 (0.68–1.05) 1.22 (0.98–1.52) 1.31 (1.03–1.68) 0.001
Model F: confounders + CRP
HR (95 % CI)
1 (reference) 0.96 (0.77–1.20) 1.16 (0.92–1.45) 1.38 (1.07–1.79) 0.021
Model G: confounders + Hb, CRP, TSH
HR (95 % CI)
1 (reference) 0.84 (0.64–1.09) 1.20 (0.92–1.56) 1.26 (0.93–1.70) 0.025
aAcross quartiles
Model A: unadjusted; Model B: unadjusted with removal of baseline CVD/cancer; Model C: Model B + statistically proven confounders – age, gender, body mass
index, marital status, smoking, education, alcohol, social class, diet, physical activity, beta blocker, depression, pain, diabetes; Model D: Model C plus Hb adjusted;
Model E: Model C plus TSH adjusted; Model F: Model C plus CRP adjusted; Model G: Model C plus Hb, CRP and TSH adjusted
CI confidence interval, CRP C-reactive protein, CVD cardiovascular disease, Hb haemoglobin, HR hazard ratio, TSH thyroid-stimulting hormone
Table 4 The risks of cancer related mortality by SF36 vitality score in the EPIC-Norfolk study
Mortality SF36 vitality score quartiles p valuea
76–100 65–75 50–64 0–49
Model A: unadjusted full dataset
HR (95 % CI)
1 (reference) 0.97 (0.84–1.16) 1.16 (1.01–1.33) 1.10 (0.95–1.27) 0.043
Model B: unadjusted with removal
of baseline CVD/cancer
HR (95 % CI)
1 (reference) 0.95 (0.82–1.10) 1.10 (0.95–1.28) 0.98 (0.83–1.15) 0.237
Model C: confounders
HR (95 % CI)
1 (reference) 0.96 (0.83–1.13) 1.14 (0.96–1.34) 1.09 (0.90–1.32) 0.185
Model D: confounders + Hb
HR (95 % CI)
1(reference) 0.94 (0.79–1.11) 1.16 (0.97–1.38) 1.12 (0.91–1.38) 0.086
Model E: confounders + TSH
HR (95 % CI)
1 (reference) 0.91 (0.75–1.10) 1.13 (0.93–1.38) 0.98 (0.77–1.24) 0.132
Model F: confounders + CRP
HR (95 % CI)
1 (reference) 1.06 (0.88–1.27) 1.18 (0.97–1.44) 1.09 (0.87–1.37) 0.385
Model G: confounders + Hb, CRP,TSH
HR (95 % CI)
1 (reference) 1.04 (0.84–1.29) 1.19 (0.95–1.51) 0.86 (0.65–1.15) 0.081
aAcross quartiles
Model A: unadjusted; Model B: unadjusted with removal of baseline CVD/cancer; Model C: Model B + statistically proven confounders – age, gender, body mass
index, marital status, smoking, education, alcohol, social class, diet, physical activity, beta blocker, depression, pain, diabetes; Model D: Model C plus Hb adjusted;
Model E: Model C plus TSH adjusted; Model F: Model C plus CRP adjusted; Model G: Model C plus Hb, CRP and TSH adjusted
CI confidence interval, CRP C-reactive protein, CVD cardiovascular disease, Hb haemoglobin, HR hazard ratio, TSH thyroid-stimulting hormone
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characterised as disabling and lasting for >6 months
[21]. Because our data evidences a consistent dose re-
sponse between fatigue severity and mortality, these pa-
tients are likely to be at even greater risk of premature
death in comparison to the population described in this
study. These data may, however, not be used to infer the
prognosis of patients with chronic fatigue syndrome be-
cause information on total fatigue duration was not
measured and this may also represent a distinct disorder.
Indeed, recent evidence suggests that such patients have
a different risk factor profile compared to the general
population in terms of mortality causes [22].
Second, there is the potential for pre-existing baseline
morbidities, especially CVD, to exaggerate the true associ-
ation between fatigue and premature mortality. We
attempted to address such reverse causality within the
analysis by excluding participants who reported baseline
CVD and cancer. To further exclude the influence of pos-
sible subclinical disease, deaths within 2 years were ex-
cluded and baseline aspirin use, a surrogate marker of
high CVD risk, was submitted as a covariate. Neither re-
sulted in a meaningful modification of the final models.
Third, there are potential measurement errors in the
assessment of exposures. We only used a single measure
at one time point to assess each confounder and so did
not take into account possible changes over the follow-
up period. That said, such random measurement error
would probably attenuate any associations observed, so
the estimated differences in risk are likely to be larger
than those observed.
In relation to other prognostic factors of mortality, which
are already considered key targets for intervention in
modern-day health services, the observed unadjusted mor-
tality risk of high fatigue (HR 1.63, 95 % CI 1.40–1.89) is
similar to being a current smoker (HR 1.35, 95 % CI 1.24–
1.48, see Additional file 1: Table S2) in this same sample
(although direct comparisons of HRs are not possible
owing to differences in the measurement scale). These re-
sults are even more meaningful from a public health per-
spective given the highly prevalent nature of fatigue. Hardy
et al. [10] and Moreh et al. [9] also reported similarly sized
effects of fatigue on mortality (adjusted HR 1.40, 95 % CI
1.08–1.93 and 1.31, 0.92–1.86, respectively) although their
study populations were restricted to the elderly and were
small (n = 492 and n = 605, respectively), so did not deter-
mine cause-specific mortality [9, 10]. Furthermore, both
utilised an unvalidated single item question to measure fa-
tigue, failed to investigate key putative mechanisms such as
thyroid status and inflammation, and did not account for
the possibility of reverse causality as we have.
Knowledge regarding the mechanisms which cause fa-
tigue is limited and the precise pathophysiology of fatigue
has yet to be elucidated. Possible insights may be derived
from research examining the concept of ‘burnout’ – a
multidimensional construct consisting of emotional ex-
haustion, cognitive weariness and physical fatigue. Intri-
guingly, this is also associated with all-cause mortality, in
particular CVD [23]. This state has been characterised by
reduced hypothalamic pituitary adrenal axis responses
[24], low grade inflammation [25] and impaired fibrino-
lytic capacities [26], all of which have also been independ-
ently associated with CVD [27–29]. It is interesting that
our study also identified inflammation, as measured by
CRP, to be a potentially relevant mechanism. We have also
identified the importance of TSH. Of the multiple func-
tions of this hormone, its positive influence on the basal
metabolic rate and on catecholamine sensitivity best ex-
plain why low levels commonly manifest as fatigue [30].
Furthermore, the hypothyroid state is associated with ac-
celerated atherosclerosis, systemic vascular resistance and
subsequent CVD [31]. Though this study does not directly
inform whether thyroxine replacement (in those with high
abnormal TSH level) would attenuate the mortality risk of
fatigue, the data in combination with existing biological
knowledge does strongly allude to this.
The persisting significant risk despite adjustment of al-
most all routinely considered associations highlights the
need for greater therapeutic options in this field. This can-
not be achieved without further research in this area to
unravel the likely complex mechanisms. Based on our
findings, such biological mechanisms may be shared with
CVD, providing a starting point for further investigation,
but other behavioural and psychosocial factors, for ex-
ample work-shift patterns, should also be considered.
Being in the highest quartile for self-reported fatigue is
significantly predictive of death and on a par with recog-
nised risk factors such as active smoking. The risk is
likely to be even greater for those presenting with more
severe symptoms and is especially associated with CVD-
related death. This study therefore indicates the poten-
tial seriousness of this frequently dismissed symptom
[7]. The attenuation of risk by both behavioural and clin-
ical factors in our models suggests a potential benefit of
a comprehensive bio-psychosocial approach. In the fu-
ture, fatigued persons may benefit from both non-
pharmacological interventions, for example physical
activity, and pharmacological interventions, for example
anti-inflammatory agents.
Conclusions
This study presents the first reliable evidence linking the
common symptom of fatigue with excess mortality. Patients
have long recognised the importance of fatigue [7]. The
biomedical community should now align with this pa-
tient priority and more optimally research this problem
because further elucidation and targeting of the mecha-
nisms may not only improve crucial patient reported
outcomes but conceivably improve life longevity as well.
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